Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer

Guo L, Zhang H, Shao W, Chen B

Drug Design, Development and Therapy 2015, 9:5491-5497

Published Date: 3 October 2015